This HTML5 document contains 84 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n4http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00673/identifier/drugbank/
dctermshttp://purl.org/dc/terms/
n22http://linked.opendata.cz/resource/AHFS/
n13http://linked.opendata.cz/resource/mesh/concept/
n16http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00673/identifier/national-drug-code-directory/
n17http://linked.opendata.cz/resource/drugbank/dosage/
n15http://bio2rdf.org/drugbank:
n24http://linked.opendata.cz/resource/drugbank/drug/DB00673/identifier/chebi/
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/patent/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00673/identifier/wikipedia/
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/resource/drugbank/medicinal-product/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00673/identifier/pharmgkb/
owlhttp://www.w3.org/2002/07/owl#
n12http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n21http://www.drugs.com/cdi/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00673
rdf:type
n5:Drug
n5:description
Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).
n5:dosage
n17:271B4154-363D-11E5-9242-09173F13E4C5 n17:271B4155-363D-11E5-9242-09173F13E4C5 n17:271B4156-363D-11E5-9242-09173F13E4C5 n17:271B4157-363D-11E5-9242-09173F13E4C5 n17:271B4158-363D-11E5-9242-09173F13E4C5 n17:271B4159-363D-11E5-9242-09173F13E4C5
n5:group
approved investigational
n5:halfLife
9-13 hours
n5:indication
For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).
n5:manufacturer
n16:271B4148-363D-11E5-9242-09173F13E4C5
owl:sameAs
n10:DB00673 n15:DB00673
dcterms:title
Aprepitant
adms:identifier
n8:PA164747039 n23:0006-0461-02 n24:499361 n25:Aprepitant n26:DB00673
n5:mechanismOfAction
Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with Aprepitant have shown that it crosses the blood brain barrier and occupies brain NK1 receptors. Animal and human studies show that Aprepitant augments the antiemetic activity of the 5-HT<sub>3</sub>-receptor antagonist ondansetron and the corticosteroid ethasone and inhibits both the acute and delayed phases of cisplatin induced emesis.
n5:packager
n16:271B4147-363D-11E5-9242-09173F13E4C5 n16:271B4146-363D-11E5-9242-09173F13E4C5
n5:patent
n14:2469315 n14:6096742 n14:5145684
n5:routeOfElimination
Aprepitant is eliminated primarily by metabolism; aprepitant is not renally excreted. Aprepitant is excreted in the milk of rats. It is not known whether this drug is excreted in human milk.
n5:synonym
Aprepitant 3-(((2R,3S)-3-(P-Fluorophenyl)-2-(((alphar)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(2)-1,2,4-triazolin-5-one Aprépitant Aprepitantum
n5:volumeOfDistribution
* 70 L
n19:hasAHFSCode
n22:56-22-92
n5:foodInteraction
Take without regard to meals.
n5:proteinBinding
>95%
n5:synthesisReference
Mangesh Shivram Sawant, Girish Dixit, Nitin Sharad Chandra Pradhan, Mubeen Ahmad Khan, Sukumar Sinha, "Amorphous and Crystalline Forms of Aprepitant and Processes for the Preparation Thereof." U.S. Patent US20090192161, issued July 30, 2009.
n12:hasConcept
n13:M0447596
foaf:page
n4:emend.htm n21:aprepitant.html
n5:IUPAC-Name
n6:271B415E-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B4164-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B4163-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B4160-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B4161-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B4162-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B4174-363D-11E5-9242-09173F13E4C5 n6:271B415C-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B415D-363D-11E5-9242-09173F13E4C5 n6:271B4175-363D-11E5-9242-09173F13E4C5 n6:271B415A-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B415B-363D-11E5-9242-09173F13E4C5
n19:hasATCCode
n20:A04AD12
n5:H-Bond-Acceptor-Count
n6:271B416A-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B416B-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B4165-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B4166-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B4168-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B4167-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B4169-363D-11E5-9242-09173F13E4C5
n5:absorption
The mean absolute oral bioavailability of aprepitant is approximately 60 to 65%.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
170729-80-3
n5:clearance
* Apparent plasma cl=62-90 mL/min
n5:containedIn
n11:271B414B-363D-11E5-9242-09173F13E4C5 n11:271B414E-363D-11E5-9242-09173F13E4C5 n11:271B4149-363D-11E5-9242-09173F13E4C5 n11:271B414C-363D-11E5-9242-09173F13E4C5 n11:271B414A-363D-11E5-9242-09173F13E4C5 n11:271B414D-363D-11E5-9242-09173F13E4C5 n11:271B4151-363D-11E5-9242-09173F13E4C5 n11:271B4152-363D-11E5-9242-09173F13E4C5 n11:271B414F-363D-11E5-9242-09173F13E4C5 n11:271B4150-363D-11E5-9242-09173F13E4C5 n11:271B4153-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B4170-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B4172-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B4173-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B416F-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B416E-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B4171-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B415F-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B416C-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B416D-363D-11E5-9242-09173F13E4C5